The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

The male patient experienced fever, body aches, and a reddish skin rash, while the female patient had fever, swollen limbs, and joint pain ...